Problems loom large for British health and social care. Like many other European countries, a number of these problems are domestic: the UK has an ageing population with the demands on the NHS and social care growing at a near-exponential rate, and raising questions as to how public services can be funded in future. But Brexit has also raised questions about how it will be resourced.
Regulation – a brief introduction
On the face of it, leaving the EU shouldn’t mean a great deal for health and social care. It is, after all, a closely guarded national competency by every member state. And, as part of the Leave campaign in the UK, suggestions abounded (albeit hotly contested ones) that Brexit could result in more funding for the NHS.
But it’s a mistake to think the EU has no role to play. Indeed, its influence is extensive. European regulations affect the pharmaceuticals market and medical technology markets, procurement and working time regulations – i.e. how much time a doctor can work per week. The EU has also introduced the European Health Insurance Card, which enables citizens falling ill in another member state to receive free at point of delivery healthcare.
The European Medicines Agency is also based in London, with responsibility for:
- Scientific evaluation of human and veterinary medicines for use in the EU
- Marketing authorisations for medicines, allowing their use across the EU, Iceland, Liechtenstein and Norway
The UK is a member of the European Centre for Disease Control and Prevention to help respond to the threat of communicable diseases. And there’s the EU Tobacco Products Directive, which is an example of the EU’s work in public health.
Finally, but very importantly, is a European Directive that allows health and social care professionals to have their qualifications recognised by the relevant regulator in any EEA country. The result? Nearly 5% of all NHS staff – and 10% of all doctors – are from other EU countries. Nearly 20% of social care workers were also born outside the UK.
A new NHS Europe Transition team has been established to work in the UK Cabinet Office and Department of Health. Why? To ensure patient interests are heard, with concerns increasing over the possible consequences for health and social care
- Some restriction on freedom of movement will be a major topic of Brexit negotiations. The restriction of movement could exacerbate an existing staffing and recruitment crisis in the NHS – but also pose challenges for MedTech and pharma companies looking for skilled staff, depending on the final shape of any new rules
- Pharmaceuticals could face disruption or duplication of processes required to get new medicines authorised
- Divergence between UK and EU regulation for pharmaceuticals and medical technology if the UK leaves the single market would not necessarily be helpful
- The UK will be exempt from the EU’s Working Time Directive – which could influence the working patterns of health and social care professionals
- There could be reductions in funding for science and medical research in the UK with the loss of EU funding and grants
- The departure from the EU could result in additional funding for the health service
- There is some speculation that limiting EU immigration could open up more non-EU immigration – but this remains to be seen
- Government is unlikely to enact wholesale changes to NHS procurement models – this will allow suppliers a measure of certainty